Chemotherapy-induced Peripheral Neuropathy: CIPN
Keywords:
chemotherapy, peripheral neuropathy, adverse effectAbstract
Peripheral Neuropathy is a common complication of certain chemotherapeutic agents. The prevalences of chemotherapy-induced peripheral neuropathy (CIPN) accounted for 68.1%, 60.0%, and 30%, in months 1, 3, and 6 after treatment course, consecutively. Common reported symptoms of CIPN involve the sensory system and are likely to occur symmetrically, typically spreading in a glove-stocking pattern. This can result in diminished deep-tendon reflexes. In contrast, motor-system symptoms are rare. The most common anti-cancer agents often associated with peripheral neuropathy are platinum analogs, taxanes, vinca alkaloids, immunomodulatory drugs (IMiDs) and proteasome inhibitors. The pathophysiological mechanisms of each agent are distinct but poorly understood. Due to current advances in cancer care, a huge increase in the number of cancer survivors is expected. There is a need for caution about the potential long-term adverse effects of cancer therapy, such as CIPN, which can have significant impacts on patients' quality of life
References
Addington J, Freimer M. Chemotherapy-induced peripheral neuropathy: an update on the current understanding. F1000Res 2016;5:1466.
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and metaanalysis. Redox Biol 2014;2:289-95.
Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, et al. Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA Cancer J Clin 2013;63:419-37.
Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy. Semin Oncol 2006;33:15-49.
Wang XM, Lehky TJ, Brell JM, Dorsey SG. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine 2012;59:3-9.
Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute Oxaliplatin-Induced Peripheral Nerve Hyperexcitability. J Clin Oncol 2002;20:176774.
Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, Tassi R, et al. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol 2007;61:105-11.
Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011;12:642-53.
Cersosimo RJ. Cisplatin neurotoxicity. Cancer Treat Rev 1989;16:195-211.
Ozols RF, Bundy BN, Greer BE, Fowler JM, ClarkePearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2013;21:3194-200.
Grothey A. Oxaliplatin-safety profile: Neurotoxicity. Semin Oncol 2003;30:5-13.
Smith RE, Brown AM, Mamounas EP, Anderson SJ, Lembersky BC, Atkins JH, et al. Randomized Trial of 3-Hour Versus 24-Hour Infusion of High-Dose Paclitaxel in Patients With Metastatic or Locally Advanced Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 1999;17:3403-11.
Mielke S, Mross K, Gerds TA, Schmidt A, Wäsch R, Berger DP, et al. Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anticancer Drugs 2003;14785-92.
Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, et al. Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks. J Clin Oncol 2005;23:5983-92.
Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, et al. Cremophor ELmediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications. Cancer Res 1999;59:1454-7.
New PZ, Jackson CE, Rinaldi D, Burris H, Barohn RJ. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996;46:108-11.
Vishnu P, Roy V. Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer. Breast Cancer (Auckl) 2011;5:53-65.
Desai N. Nanoparticle Albumin-Bound Paclitaxel (Abraxane). Albumin in Medicine. Singapore: Springer; 2016. p.101-19.
Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249:9-17.
Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 2005;64:1076-7.
Moriyama B, Henning SA, Leung J, Falade-Nwulia O, Jarosinski P, Penzak SR, et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses 2011;55: 290-7.
Briani C, Torre CD, Campagnolo M, Lucchetta M, Berno T, Candiotto L, et al. Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study. J Peripher Nerv Syst 2013;18:19-24.
Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib. J Clin Oncol 2006;24:3113-20.
Delforge M, Bladé J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010;11:1086-95.
Vij R, Wang L, Orlowski RZ, Stewart AK, Jagannath S ,Lonial S, et al. Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects. Blood 2009;114:430.
Mollman JE, Glover DJ, Hogan WM, Furman RE. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 1988;61:2192-5.
Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and metaanalysis. Redox Biol 2014;2:289-95.
Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, et al. Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA Cancer J Clin 2013;63:419-37.
Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy. Semin Oncol 2006;33:15-49.
Wang XM, Lehky TJ, Brell JM, Dorsey SG. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine 2012;59:3-9.
Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute Oxaliplatin-Induced Peripheral Nerve Hyperexcitability. J Clin Oncol 2002;20:176774.
Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, Tassi R, et al. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol 2007;61:105-11.
Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011;12:642-53.
Cersosimo RJ. Cisplatin neurotoxicity. Cancer Treat Rev 1989;16:195-211.
Ozols RF, Bundy BN, Greer BE, Fowler JM, ClarkePearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2013;21:3194-200.
Grothey A. Oxaliplatin-safety profile: Neurotoxicity. Semin Oncol 2003;30:5-13.
Smith RE, Brown AM, Mamounas EP, Anderson SJ, Lembersky BC, Atkins JH, et al. Randomized Trial of 3-Hour Versus 24-Hour Infusion of High-Dose Paclitaxel in Patients With Metastatic or Locally Advanced Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol 1999;17:3403-11.
Mielke S, Mross K, Gerds TA, Schmidt A, Wäsch R, Berger DP, et al. Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anticancer Drugs 2003;14785-92.
Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, et al. Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks. J Clin Oncol 2005;23:5983-92.
Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, et al. Cremophor ELmediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications. Cancer Res 1999;59:1454-7.
New PZ, Jackson CE, Rinaldi D, Burris H, Barohn RJ. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 1996;46:108-11.
Vishnu P, Roy V. Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer. Breast Cancer (Auckl) 2011;5:53-65.
Desai N. Nanoparticle Albumin-Bound Paclitaxel (Abraxane). Albumin in Medicine. Singapore: Springer; 2016. p.101-19.
Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249:9-17.
Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 2005;64:1076-7.
Moriyama B, Henning SA, Leung J, Falade-Nwulia O, Jarosinski P, Penzak SR, et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses 2011;55: 290-7.
Briani C, Torre CD, Campagnolo M, Lucchetta M, Berno T, Candiotto L, et al. Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study. J Peripher Nerv Syst 2013;18:19-24.
Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib. J Clin Oncol 2006;24:3113-20.
Delforge M, Bladé J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010;11:1086-95.
Vij R, Wang L, Orlowski RZ, Stewart AK, Jagannath S ,Lonial S, et al. Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects. Blood 2009;114:430.
Mollman JE, Glover DJ, Hogan WM, Furman RE. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer 1988;61:2192-5.
Downloads
Published
2019-03-29
Issue
Section
Review Articles
License
บทความทีตีพิมพ์ในวารสารโรคมะเร็งนี้ถือว่าเป็นลิขสิทธิ์ของมูลนิธิสถาบันมะเร็งแห่งชาติ และผลงานวิชาการหรือวิจัยของคณะผู้เขียน ไม่ใช่ความคิดเห็นของบรรณาธิการหรือผู้จัดทํา
